News Release

Women & Infants studying therapies to relieve urinary urge incontinence

Participating in study as part of national Pelvic Floor Disorders Network

Business Announcement

Care New England

Overactive bladder, or the sudden urge to urinate, affects the quality of life of many women. Studies have shown that not all women respond to or can tolerate oral medications and may benefit from other therapies.

Women & Infants Hospital of Rhode Island is conducting a study to compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. Patients are currently being enrolled in the ROSETTA Study – Reftractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment. The ROSETTA Study is part of the national Pelvic Floor Disorders Network which is funded by the National Institute of Child Health and Development and the Office of Research on Women's Health.

Principal investigator at Women & Infants is Deborah Myers, MD, director of the Division of Urogynecology and Reconstructive Pelvic Surgery at Women & Infants and at The Warren Alpert Medical School of Brown University.

"There are more than 10 million women who suffer from incontinence in America today and more than 50,000 women in Rhode Island alone. That's about one in four between the ages of 30 and 59," said Dr. Myers. "For some women, medications and physical therapy may not help. If we can find another therapy option for these women, we can dramatically impact their quality of life. That's what studies like ROSETTA are all about."

The ROSETTA Study will compare the effect of two therapies in women who have bothersome urinary urge incontinence after trying other treatments. The two new treatments are:

  • Botox®, a medication injected into the bladder, or
  • InterStim® Therapy, a reversible treatment that uses mild electrical pulses to stimulate nerves going to the bladder (neuromodulation) that influence bladder function.

Women who may be eligible to participate are over 21 years of age, report symptoms of urge incontinence or overactive bladder, experience this leakage two or more times a day, and have tried other treatments including oral medication. Participation will include receiving one of the two procedures and monthly office visits or telephone follow-up for six months and follow-up every three to six months for 24 months.

###

For information about the ROSETTA Study, call the research coordinator at Women & Infants' Center for Women's Pelvic Medicine and Reconstructive Surgery at (401) 276-7869 or visit womenandinfants.org.

About Women & Infants Hospital

Women & Infants Hospital of Rhode Island, a Care New England hospital, is one of the nation's leading specialty hospitals for women and newborns. A U.S.News Best Hospital in Gynecology and Best Children's Hospital in Neonatology, Women & Infants was ranked number one in the Providence metro area and a top-performer in cancer, and has achieved a 5-star rating in Maternity Care for 2011 from HealthGrades. The primary teaching affiliate of The Warren Alpert Medical School of Brown University for obstetrics, gynecology and newborn pediatrics, as well as a number of specialized programs in women's medicine, Women & Infants is the eighth largest stand-alone obstetrical service in the country with more than 8,500 deliveries per year. In 2009, Women & Infants opened the country's largest, single-family room neonatal intensive care unit.

New England's premier hospital for women and newborns, Women & Infants and Brown offer fellowship programs in gynecologic oncology, maternal-fetal medicine, urogynecology and reconstructive pelvic surgery, neonatal-perinatal medicine, pediatric and perinatal pathology, gynecologic pathology and cytopathology, and reproductive endocrinology and infertility. It is home to the nation's only mother-baby perinatal psychiatric partial hospital, as well as the nation's only fellowship program in obstetric medicine.

Women & Infants has been designated as a Breast Center of Excellence from the American College of Radiography; a Center for In Vitro Maturation Excellence by SAGE In Vitro Fertilization; a Center of Biomedical Research Excellence by the National Institutes of Health; and a Neonatal Resource Services Center of Excellence. It is one of the largest and most prestigious research facilities in high risk and normal obstetrics, gynecology and newborn pediatrics in the nation, and is a member of the National Cancer Institute's Gynecologic Oncology Group and the National Institutes of Health's Pelvic Floor Disorders Network.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.